Chinese biotechnology company Clover Biopharmaceuticals has signed an exclusive agreement with Taiwan-based Adimmune to sell the latter’s AdimFlu-S (QIS) in mainland China.

AdimFlu-S (QIS) is said to be the only imported quadrivalent seasonal influenza vaccine approved in China. It was approved by the China National Medical Products Administration in January 2022 for use in individuals aged three and older.

As per the terms of the agreement, Clover Biopharmaceuticals also gets the rights to commercialise the quadrivalent split inactivated vaccine in Bangladesh, Brazil, and the Philippines, subject to regulatory approvals.

The deal also allows the Chinese firm for potential collaboration with Adimmune on the development of additional vaccine candidates like next-generation influenza vaccines.

Clover Biopharmaceuticals CEO and executive director Joshua Liang said: “We are delighted to form this strategic partnership with Adimmune, a company with a stellar track record in manufacturing and supplying critical vaccines to populations in Asia—particularly as the market for flu vaccines generally, and quadrivalent vaccines specifically, is poised for significant growth in mainland China.

“This partnership also brings Clover one step closer to establishing a leading respiratory vaccine franchise, and allows us to realise synergies with the ongoing commercialization of our COVID-19 vaccine.”

Expected to be launched in the latter half of this year, Clover Biopharmaceuticals  will be in charge of distributing the vaccine across all of mainland China.

The Chinese biotechnology company will use its commercial infrastructure and sales organisation to market the vaccine, where it is already approved.

Adimmune will produce AdimFlu-S (QIS) at its production facility, which has been approved for good manufacturing procedures (GMP) by the US Food and Drug Administration, the European Medicines Agency, and other organisations.

Adimmune chairman and CEO Chi-Hsien Chan said: “We are very pleased to partner with Clover, with its growing commercial presence in mainland China and impressive record of successful cross-border collaboration.

“We also have a shared commitment to improving seasonal influenza vaccination coverage, particularly for elderly populations who are most at-risk, with our high-quality quadrivalent vaccine.”